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Abstract
The ability of liposomes bearing anti-HLA-DR FabP fragments at the end termini of polyethyleneglycol chains (sterically
stabilized immunoliposomes) to target HLA-DR expressing cells and increase the accumulation of liposomes into lymphoid
organs has been evaluated and compared to that of conventional liposomes, sterically stabilized liposomes and conventional
immunoliposomes after a single subcutaneous injection to mice. The accumulation of sterically stabilized liposomes in lymph
nodes was higher than that of conventional liposomes. Sterically stabilized immunoliposomes accumulated much better than
conventional immunoliposomes in all tissues indicating that the presence of PEG has an important effect on the uptake of
immunoliposomes by the lymphatic system. Fluorescence microscopy studies showed that sterically stabilized liposomes are
mainly localized in macrophage-rich areas such as the subcapsular region of lymph nodes and in the red pulp and marginal
zone of the spleen. In contrast, sterically stabilized immunoliposomes mostly accumulated in the cortex in which follicles are
located and in the white pulp of the spleen. As the human HLA-DR determinant of the major histocompatibility complex
class II is expressed on activated CD4+ T lymphocytes and antigen presenting cells such as monocyte/macrophages and
dendritic cells, known as the cellular reservoirs of HIV-1, liposomes bearing anti-HLA-DR antibodies constitute an attractive
approach to concentrate drugs in HIV-1 reservoirs and improve their therapeutic effect. ß 2000 Elsevier Science B.V. All
rights reserved.
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1. Introduction
It is well established that lymphoid tissues are the
major reservoirs of human immunode¢ciency virus
type-1 (HIV-1) [1^5]. During primary infection,
HIV-1 particles disseminate rapidly in the lymphoid
organs where they replicate actively in CD4+ T-cells.
In the period of clinical latency, HIV-1 becomes
trapped onto the follicular dendritic cell (FDC) net-
work, located in the germinal centers of the second-
ary lymphoid organs, and persistently infects acti-
vated CD4+ T-cells [6]. In the advanced stage of
the disease, the microenvironment network within
the germinal centers is destroyed, and the incapacity
of FDC to retain HIV-1 particles has been postu-
lated to contribute to the increased viral burden in
the periphery [1]. As peripheral lymphoid tissues play
a crucial role in e¡ective immune response, it is im-
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portant to reduce or abrogate the production and the
accumulation of HIV-1 particles in these tissues to
preserve both their architecture and integrity.
Fortunately, highly active antiretroviral therapy
(HAART), usually consisting in the combination of
two nucleoside analogues and one protease inhibitor,
has been shown to markedly diminish the number of
HIV-1 RNA copies in secondary lymphoid tissues
[7^9]. However, replication-competent HIV-1 was
routinely isolated from resting CD4+ T-cells, even
after 30 months of HAART, impairing the possibility
to stop the treatment [8^14]. Increasing numbers of
treatment failures resulting from toxicity, drug-resis-
tant mutants and poor compliance of patients to
drug regimen are emerging with long-term therapy
[15]. Consequently, strategies aimed at reaching ther-
apeutic levels of drugs into the lymphoid organs
should be developed to improve the e⁄cacy of
antiretroviral agents and to prevent suboptimal con-
centrations of drugs within infected cells that
could potentially lead to the development of resis-
tance.
As liposomes are naturally taken up by cells of the
mononuclear phagocyte system (MPS), liposome-
based therapy represents a convenient approach to
improve the delivery of drugs into lymphoid tissues
[16^19]. Morphological observations on the fate of
liposomes in regional lymph nodes suggest that lipo-
somes remained stable within the lymphatic circula-
tion and that they eventually enter into cells of the
lymph nodes by phagocytosis to end up in the lyso-
somal apparatus [20]. On the other hand, the cou-
pling of polyethyleneglycol (PEG) chains on the sur-
face of liposomes (sterically stabilized liposomes) was
shown to increase their ability to move through the
lymph after subcutaneous injection and to decrease
their rate of uptake by the MPS, increasing their
residence time within plasma and/or lymph [21,22].
Consequently, attachment of antibodies to sterically
stabilized liposomes represents an attractive strategy
to combine prolonged circulation time and e⁄cient
delivery of therapeutic drugs to speci¢c cell popula-
tion and/or pathogen.
FDC, B lymphocytes, activated CD4+ T-cells and
antigen presenting cells like macrophages are abun-
dant in lymphoid tissues and all express substantial
levels of the HLA-DR determinant of the major his-
tocompatibility complex class II (MHC-II). In addi-
tion, it is well known that many enveloped viruses,
including HIV-1, acquire host cell surface molecules
during the budding process. It has been reported that
the HLA-DR determinant is physically present on
the virion surface and constitutes one of the most
abundant host-derived molecules carried by HIV-1
[23,24]. Liposomes bearing surface-attached anti-
HLA-DR antibodies thus constitute an interesting
approach to target speci¢cally HIV-1 reservoirs as
well as free HIV-1 particles trapped in the FDC net-
work. In the present study, the ability of liposomes
bearing anti-HLA-DR FabP fragments at the end
termini of PEG chains (sterically stabilized immuno-
liposomes) to target HLA-DR expressing cells and
increase their accumulation in secondary lymphoid
organs has been evaluated and compared to that of
conventional liposomes, sterically stabilized lipo-
somes and conventional immunoliposomes.
2. Materials and methods
2.1. Materials
Dipalmitoylphosphatidylcholine (DPPC), dipalmi-
toylphosphatidylglycerol (DPPG) and distearoyl-
phosphatidylethanolamine-N-[poly(ethyleneglycol)-
2000] (DSPE-PEG) were purchased from Avanti Po-
lar Lipids (Alabaster, AL, USA). Dipalmitoylphos-
phatidylethanolamine-N-(4-(p-maleimidophenyl)bu-
tyryl) (DPPE-MPB) was purchased from Northern
Lipids (Vancouver, BC, Canada) and distearoylphos-
phatidylethanolamine-[poly(ethyleneglycol)2000]-N-
(4-(p-maleimidophenyl)butyryl) (DSPE-PEG-MPB)
was custom-synthesized by Shearwater Polymers
Inc. (Huntsville, AL, USA). [3H]cholesterylhexa-
decylether was purchased from NEN Life Science
Products (Boston, MA, USA). 1,1P-dioctadecyl-
3,3,3P,3P-tetramethylindocarbocyanine perchlorate
(DiI) was purchased from Molecular Probes (Eu-
gene, OR, USA). Lysyl endopeptidase obtained
from Achromobacter lyticus was purchased from
Wako Chemicals (Richmond, VA, USA).
2.2. Preparation of antibodies
Monoclonal antibodies IgG2b (clone Y-17, clone
OKT4, ATCC, Rockville, MD, USA) that react
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with I-E subregion products (murine HLA-DR) or
human CD4 was isolated from ascites £uids and pu-
ri¢ed using a protein G a⁄nity column (Pharmacia,
Baie d’Urfe¤, QC, Canada). Antibodies were sterilized
on 0.22 Wm low binding protein ¢lters (Millipore,
Bedford, MA, USA) and stored at 320‡C in phos-
phate bu¡ered saline (PBS, pH 7.4) until use. The
immunoreactivity of antibodies was tested by £ow
cytometry on freshly prepared C3H mouse spleen
cells and SUPT-1 cells. In brief, suspension of cells
(106 cells/ml) was incubated with 1 Wg of OKT4 or
biotinylated Y-17 for 30 min at 4‡C. Cells were
washed with PBS and incubated with 1 Wg R-phy-
coerythrin conjugated streptavidin (Jackson Immu-
noresearch Laboratories, West Grove, PA, USA)
for Y-17 and with 1:50 £uorescein isothiocyanate
(FITC) conjugated goat anti-mouse IgG (Cederlane
Laboratories Ltd, Hornby, ON, Canada) for OKT4
for 30 min at 4‡C. Cells were then washed three
times with PBS, ¢xed with 1% paraformaldehyde
and kept on ice under darkness until assessment of
£uorescence by £ow cytometry (Coulter Electronics,
Miami, FL, USA).
2.3. Preparation of F(abP)2 fragments
The F(abP)2 fragments were produced following
incubation of the antibody (5 mg/ml) with lysyl en-
dopeptidase (in 50 mM Tris^HCl, pH 8.5) in a 1:50
enzyme/substrate molar ratio for 2 h at 37‡C. Lysyl
endopeptidase cleaved IgG2b at Lys-228E/Cys-229
without perturbing the disul¢de bridges. The diges-
tion products contained undigested IgG, F(abP)2
and Fc fragments. The enzyme was removed by gel
chromatography on a Sephadex G-25M column
(Pharmacia, Baie d’Urfe¤, QC, Canada). Fractions
containing digestion products were determined using
a BCA protein assay reagent kit (Pierce, Rockford,
IL, USA) and pooled together. F(abP)2 fragments
were separated with a protein A a⁄nity chromatog-
raphy column (Pharmacia, Baie d’Urfe¤, QC, Cana-
da). The column retained Fc fragments and undi-
gested IgG2b whereas F(abP)2 fragments were
collected. F(abP)2 fragments (110 kDa) were then
concentrated using Centricon-50 (Amicon, Beverly,
MA, USA) and resuspended in 1 ml phosphate
EDTA bu¡er (100 mM sodium phosphate and
5 mM EDTA, pH 6.0).
2.4. Preparation of FabP fragments
F(abP)2 fragments were incubated with 6 mg of
2-mercaptoethylamine^HCl (0.05 M) for 90 min at
37‡C. This product cleaved the disul¢de bridges
between the heavy chains but preserved the disul-
¢de linkages between the heavy and light chains.
The solution was eluted on a Sephadex G-25M
column pre-equilibrated with acetate^EDTA bu¡-
er (100 mM anhydrous sodium acetate, 88 mM
sodium chloride and 1 mM EDTA, pH 6.5) and
FabP fragments were collected in 1 ml fractions.
Fractions containing FabP fragments were deter-
mined using a BCA protein assay (Pierce, Rockford,
IL, USA) and pooled together. The FabP fragments
(55 kDa) were concentrated using Centricon-10, re-
suspended in acetate^EDTA bu¡er and kept under
nitrogen atmosphere at 4‡C until coupling to lipo-
somes.
2.5. Preparation of (immuno)liposomes
Fig. 1 shows a schematic representation of the dif-
ferent liposomal formulations used in this study.
Liposomes composed of DPPC/DPPG/DPPE-MPB
(10:3:0.33 mol/mol) for immunoliposomes and
DPPC/DPPG/DSPE-PEG-MPB (10:3:0.83 mol/
mol) for sterically stabilized immunoliposomes were
prepared according to the method of thin lipid ¢lm
hydration. In brief, the lipid mixture was dissolved in
chloroform in a round-bottomed £ask and the or-
ganic solvent was evaporated to form a thin lipid
¢lm. In some experiments, [3H]cholesterylhexa-
decylether (0.3 WCi/Wmol lipid) was added as a radio-
active tracer. The lipid ¢lm was then hydrated with
acetate^EDTA bu¡er (pH 6.5). Multilamellar
vesicles were sequentially extruded through 0.2 and
0.1 Wm polycarbonate membranes (Nuclepore, Cam-
bridge, MA, USA) using a stainless steel extrusion
device (Lipex Biomembranes, Vancouver, BC, Cana-
da). The mean vesicle size of the liposomes, as eval-
uated with a submicron particle analyzer (Coulter
Electronics, Hialeah, FL, USA), was between 100
and 118 nm. The ¢nal concentration of liposomes
was determined using an enzymatic colorimetric
method (phospholipids B kit, Wako Chemicals,
Richmond, VA, USA). Conventional liposomes
were prepared as above except that no DPPE-MPB
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was incorporated in the lipid composition. In the
case of sterically stabilized liposomes, DSPE-PEG-
MPB was replaced by DSPE-PEG.
2.6. Coupling reaction
Freshly prepared liposomes were incubated with
freshly prepared FabP fragments (35 Wg FabP/Wmol
lipid) overnight at 4‡C under continuous agitation
and under nitrogen atmosphere. Liposomes bearing
surface-attached antibodies (immunoliposomes) were
separated from unconjugated FabP fragments by ul-
tracentrifugation (100 000Ug, two times for 45 min
at 4‡C) and immunoliposomes were resuspended in
PBS (pH 7.4). The total amount of FabP conjugated
to liposomes (5^15 Wg/Wmol of lipids) was evaluated
with the Coomassie protein assay reagent (Pierce,
Rockford, IL, USA). The speci¢city and a⁄nity of
immunoliposomes toward the antigen has been pre-
viously demonstrated [25].
2.7. In vitro binding and speci¢city of
immunoliposomes
The binding and speci¢city of sterically stabilized
liposomes and immunoliposomes were evaluated on
freshly prepared C3H mouse spleen cells by £ow cy-
tometry assay. In brief, suspension of cells (106 cells/
ml) was incubated with 1.5 Wmol of DiI-labeled con-
ventional liposomes, immunoliposomes, sterically
stabilized liposomes or immunoliposomes. Samples
were washed and resuspended in PBS. The speci¢city
of liposomes for cells was determined by £ow cyto-
metry from the £uorescence associated to DiI (£uo-
rochrome incorporated into the lipid membrane).
Controls consisted of a commercial biotinylated Y-
17 antibody (Cederlane Laboratories Ltd, Hornby,
ON, Canada) and a isotype-matching irrelevant mu-
rine monoclonal antibody (OKT4) or FabP fragment
coupled to conventional liposomes or sterically sta-
bilized liposomes. No decrease in speci¢city of im-
munoliposomes (conventional or sterically stabilized)
was observed for up to 3 weeks as revealed by £ow
cytometry analysis.
2.8. Tissue distribution
A single bolus injection of conventional liposomes,
sterically stabilized liposomes, conventional immuno-
liposomes or sterically stabilized immunoliposomes
(2 Wmol lipids/500 Wl) was administered subcutane-
ously in the upper back below the neck of female
C3H mouse (18^20 g; Charles River Breeding Labo-
ratories, St-Constant, QC, Canada). At speci¢c time
points, animals were killed and blood was collected
and the plasma was separated by centrifugation
(6000Ug for 10 min at 4‡C). At the same time, se-
lected tissues were collected, washed in PBS and
weighed. Tissues and plasma were then treated with
Beckman tissue solubilizer (Beckman Instruments
Inc., Irvine, CA, USA) and decolored with H2O2.
Lipid levels in all samples were monitored by scintil-
lation countings. Six animals per group were used for
each time point.
Fig. 1. Schematic representation of conventional liposomes, sterically stabilized liposomes (PEG-coated), conventional immunolipo-
somes bearing FabP fragments and sterically stabilized immunoliposomes bearing FabP fragments at the end termini of PEG chains.
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2.9. Liposome £uorescent labeling
Liposomal lipids (2.5 mg/ml) were incubated with
10 Wg/ml of DiI under darkness for 1 h at 60‡C with
agitation. Unbound DiI was removed by centrifuga-
tion (300Ug for 15 min at 4‡C) of 1 ml of the lipo-
somal preparation through a 10 ml coarse Sephadex
G-50 column.
2.10. Tissue preparation for optical microscopy
A single bolus injection of sterically stabilized lipo-
somes and sterically stabilized immunoliposomes (2
Wmol lipid/500 Wl) was administered subcutaneously
in the upper back below the neck of female C3H
mice. At speci¢c time intervals post-injection, ani-
mals were killed and tissues (spleen, brachial and
cervical lymph nodes) were removed. Tissues were
washed in PBS, embedded in OCT Tissues Tek
(Bayer, Pointe-Claire, QC, Canada), frozen in liquid
nitrogen and stored at 320‡C. Tissue sections (10
Wm thick) were cut using a Jung Frigocut 2800E
(Leica Canada Inc., St-Laurent, QC, Canada) and
deposited on slides pretreated with 2% aminoalkysi-
lane. Coated slides were immediately observed with a
Nikon Micro£ex HFX-DX £uorescence microscope.
DiI £uorescence was observed with a rhodamine op-
tic excitation ¢lter (ex: 510^560 nm, dichroic mirror:
DM 580 and barrier ¢lter: BA 590). A minimum of
three tissues from di¡erent animals was used for each
time point.
2.11. Statistical analysis
All statistical analyses were performed using a
computer package (Statview+SE Software, Abacus
Concepts, Berkeley, CA, USA). The signi¢cance be-
tween groups was statistically evaluated using a one-
way analysis of variance (ANOVA) test, followed by
t-test with Fisher’s corrections.
3. Results
3.1. In vitro binding of sterically stabilized
immunoliposomes
Fig. 2 shows the levels of binding of sterically sta-
Fig. 2. Flow cytometry scans of mouse spleen cells incubated
with (A) DiI-labeled sterically stabilized liposomes, (B) DiI-la-
beled sterically stabilized liposomes bearing anti-HLA-DR FabP
fragments (IgG2b, clone Y-17) and (C) commercial biotinylated
Y-17 antibody revealed with R-phycoerythrin conjugated strept-
avidin. Cells alone (panel A, solid line) ; DiI-labeled sterically
stabilized liposomes bearing isotype-matching irrelevant FabP
antibody fragment (panel B, solid line) ; irrelevant biotinylated
isotype-matching antibody (panel C, solid line) ; and streptavi-
din R-phycoerythrin incubated with cells (panel C, dotted line)
were used as controls.
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bilized liposomes and immunoliposomes on C3H
mice cell spleen by £ow cytometry. DiI-labeled lipo-
somes were used to determine the speci¢city of im-
munoliposomes since we could not use a conjugated
goat anti-mouse IgG against mouse spleen cells as
non-speci¢c binding would have occurred. As ex-
pected, results clearly demonstrated that sterically
stabilized anti-HLA-DR immunoliposomes were spe-
ci¢c to cells expressing the HLA-DR determinant of
MHC-II being similar to that observed with a com-
mercial anti-HLA-DR antibody control (33.5% pos-
itive cells, mean 41.0 and 31.8% positive cells, mean
57.0, respectively). Sterically stabilized liposomes did
not bind to mouse cells as well as sterically stabilized
liposomes bearing an irrelevant non-speci¢c isotype-
matching FabP antibody fragment.
3.2. Tissue distribution
In order to evaluate if the presence of PEG mole-
cules on the surface of liposomes can prolong their
circulation time and increase their rate of lymphatic
uptake, we have ¢rst evaluated the tissue distribution
of sterically stabilized and conventional liposomes
following a single subcutaneous injection in the
upper back of C3H mice. Table 1 shows the area
under the curve of the concentration of sterically
stabilized and conventional liposomes in di¡erent tis-
sues after a period up to 240 h post-injection (time
points 24, 48, 120 and 240 h). Results show that the
accumulation of both liposome formulations was
greater in lymph nodes near the injection site (e.g.
cervical and brachial lymph nodes) when compared
Table 2
Area under the curve of sterically stabilized and conventional immunoliposomes in di¡erent tissues after the administration of a single
subcutaneous dose (2 Wmol) in C3H micea
Tissues Sterically stabilized
immunoliposomes
Conventional
immunoliposomes
Ratio sterically stabilized immuno/
conventional immuno
Cervical lymph nodes 1514.7 616.1 2.5
Brachial lymph nodes 1693.7 874.7 1.9
Mesenteric lymph nodes 16.0 5.5 2.9
Inguinal lymph nodes 34.8 15.8 2.2
Popliteal lymph nodes 70.8 26.3 2.7
Liver 61.5 25.5 2.4
Spleen 57.4 12.6 4.6
Plasma 3.6 1.7 2.2
aValues, expressed in Wmol lipids/g tissue (or ml of plasma)/h, were calculated from the mean values of the tissue distribution pro¢le
using the trapezoidal rule.
Table 1
Area under the curve of sterically stabilized and conventional liposomes in di¡erent tissues after the administration of a single subcu-
taneous dose (2 Wmol) in C3H micea
Tissues Sterically stabilized
liposomes
Conventional
liposomes
Ratio sterically stabilized/
conventional liposomes
Cervical lymph nodes 922.6 810.5 1.1
Brachial lymph nodes 1172.7 823.2 1.4
Mesenteric lymph nodes 5.7 3.6 1.6
Inguinal lymph nodes 14.0 9.9 1.4
Popliteal lymph nodes 18.0 9.3 1.9
Liver 43.2 26.8 1.6
Spleen 38.3 20.5 1.9
Plasma 1.7 1.7 1.0
aValues, expressed in Wmol lipids/g tissue (or ml of plasma)/h, were calculated from the mean values of the tissue distribution pro¢le
using the trapezoidal rule.
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to other nodes or tissues. Moreover, sterically stabi-
lized liposomes accumulated more e⁄ciently than
conventional liposomes in all lymph nodes as well
as in liver and spleen. Although very low, the accu-
mulation of sterically stabilized liposomes in plasma
was similar to that of conventional liposomes. It can
be speculated that the enhanced accumulation of
sterically stabilized liposomes in these tissues may
be due to their reduced accumulation at the injection
site and their prolonged circulation time in the lym-
phatic system which increase their uptake by lym-
phoid tissues.
We have next determined if the presence of anti-
HLA-DR FabP fragments at the end termini of PEG-
coated liposomes could also improve their tissue ac-
cumulation compared to PEG-free immunolipo-
somes. Once again, results show that the concentra-
tion of both immunoliposomal formulations was
higher in brachial and cervical lymph nodes than in
other tissues suggesting that liposomes administered
subcutaneously accumulated preferentially in the re-
gional lymph nodes (Fig. 3). In addition, sterically
stabilized immunoliposomes targeted more e⁄ciently
all tissues, with a peak of accumulation at 240 h in
Fig. 3. Tissue distribution of conventional immunoliposomes (dotted bar) and sterically stabilized immunoliposomes (solid bar) in bra-
chial, cervical, mesenteric, inguinal and popliteal lymph nodes, and spleen following a single subcutaneous injection to mice. Values
represent the mean ( þ S.E.M.) obtained for six animals per group per time point. *, and **, signi¢cantly di¡erent (P6 0.05) and
(P6 0.01), respectively when compared to conventional immunoliposomes.
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brachial, inguinal and popliteal lymph nodes. The
concentration of sterically stabilized immunolipo-
somes in mesenteric lymph nodes reached a plateau
at 24 h post-injection and the tissue distribution pro-
¢le was very similar to that observed in the spleen.
There were no signi¢cant di¡erences in the accumu-
lation of sterically stabilized and conventional immu-
noliposomes at 6 h post-injection in lymph nodes and
spleen, except for the popliteal lymph nodes, which
are the farther lymph nodes from the injection site.
The radioactive tracer in liposomes remained stable
for the time period of the experiment (data not
shown). Table 2 shows the area under the curve of
sterically stabilized and conventional immunolipo-
somes in di¡erent tissues. Results clearly demon-
strated that sterically stabilized immunoliposomes
accumulated much better than conventional immu-
noliposomes in all tissues indicating that the presence
of PEG has an important e¡ect on the uptake of
immunoliposomes by the lymphatic system.
In another set of experiments, the concentration of
the four types of liposomes was determined at 48 and
120 h after their subcutaneous administration to
C3H mice. Fig. 4 shows that the presence of PEG
Fig. 4. Tissue distribution of conventional (empty bar), sterically stabilized (lined bar), conventional immunoliposomes (dotted bar)
and sterically stabilized immunoliposomes (solid bar) in brachial, cervical, mesenteric, inguinal and popliteal lymph nodes, and spleen
following a single subcutaneous injection to mice. Values represent the mean ( þ S.E.M.) obtained for six animals per group per time
point. *, Signi¢cantly di¡erent (P6 0.05) when compared to conventional liposomes and **, signi¢cantly di¡erent (P6 0.05) when
compared to conventional immunoliposomes.
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on the surface of liposomes or immunoliposomes had
no signi¢cant e¡ect on their accumulation in the
regional lymph nodes (brachial and cervical) but
signi¢cantly increased their uptake in other lymph
nodes compared to conventional liposomes or immu-
noliposomes. On the other hand, there was no sig-
ni¢cant di¡erence in the accumulation of sterically
stabilized liposomes in the spleen when compared
to conventional liposomes at these two time points.
In contrast, the concentration of sterically stabilized
immunoliposomes in this tissue was much higher
when compared to conventional immunoliposomes.
Fig. 5. Fluorescent micrographs of brachial lymph nodes of C3H mouse at 120 h following the administration of a single subcutane-
ous dose of DiI sterically stabilized liposomes (panel A), sterically stabilized immunoliposomes (panel C) and sterically stabilized lipo-
somes bearing non-speci¢c isotype-matching FabP fragments (panel E) to mice. Panels B, D and F represent the corresponding hema-
toxylin eosin coloration of tissues. Figure shows the cortex area (C), the parafollicular area (PF), the medulla (M) and the lymphoid
follicle (LF). Magni¢cation: 250U.
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In addition, the presence of anti-HLA-DR FabP frag-
ments on both conventional and sterically stabilized
liposomes greatly improved their accumulation in re-
gional lymph nodes when compared to non-targeted
liposomes. The presence of an irrelevant isotype-
matching FabP fragment on sterically stabilized lipo-
somes had no e¡ect on the tissue distribution pro¢le
being similar to that of sterically stabilized liposomes
(data not shown).
3.3. Tissue localization
Since sterically stabilized liposomes and sterically
stabilized immunoliposomes represent the best for-
mulation to target lymphoid tissues, we have next
evaluated if the presence of anti-HLA-DR FabP frag-
ments at the end termini of PEG chains a¡ects the
tissue localization of liposomes. Fig. 5 compared the
localization of £uorescent sterically stabilized lipo-
somes and sterically stabilized immunoliposomes in
brachial lymph nodes at 120 h after their subcuta-
neous administration in mice. Results show that the
localization of sterically stabilized immunoliposomes
is very di¡erent from that of sterically stabilized lipo-
somes. Sterically stabilized liposomes are mainly lo-
calized in the subcapsular area, probably in the a¡er-
ent lymphatic vessel and around the a¡erent area. In
contrast, sterically stabilized anti-HLA-DR immuno-
liposomes mostly accumulated in the cortex in which
follicles (B-cells and FDCs) are located and in para-
follicular areas in which T-cells, interdigitating den-
dritic cells and other accessory cells are abundant.
No signi¢cant £uorescent signal was observed in
the subcapsular area of the lymph nodes when non-
speci¢c isotype-matching FabP fragments were
coupled to sterically stabilized liposomes.
Fig. 6 compared the localization of sterically sta-
bilized liposomes and sterically stabilized immuno-
liposomes in the spleen at 48 h after their subcutane-
ous administration in mice. Results show that the
accumulation of sterically stabilized immunolipo-
somes in this tissue is more important than that of
sterically stabilized liposomes and that their localiza-
tion is di¡erent. However, it should be noted that
tissue localization studies using the £uorescent
marker are qualitative and could not be used to eval-
uate the concentration of liposomes in these tissues.
In the case of sterically stabilized liposomes, a weak
£uorescence signal was observed in the marginal
zone of the white pulp. In contrast, sterically stabi-
lized immunoliposomes were largely concentrated in
the lymphoid nodules of the white pulp and little in
the marginal zone. The administration of free DiI did
not result in any £uorescent signal in all studied tis-
sues. Furthermore, the injection of DiI-labeled lipo-
somes showed a disappearance of the £uorescent sig-
nal as a function of time indicating that the probe is
eliminated with time. When non-speci¢c immuno-
liposomes were injected to mice, a weak £uorescence
signal was observed in the same area than that ob-
served for sterically stabilized liposomes suggesting
that the presence of irrelevant antibody had no e¡ect
on the tissue localization of liposomes.
4. Discussion
The introduction of triple drug therapy led to a lot
of hope for the treatment of HIV-1 infection [26^29].
However, although this therapy can reduce the plas-
ma viral load to undetectable levels, viral replication
still occurs in the lymph nodes or other sanctuary
sites of HIV-1 and this low viral level can lead to
resistant mutations [10,11,26,29,30]. It was shown
that initiation of HAART in infected individuals,
as early as 10 days after the onset of symptoms of
primary HIV-1 infection, did not prevent generation
of latently infected resting CD4+ T-cells carrying in-
tegrated HIV-1 DNA despite the successful control
of plasma viremia [31]. Since new anti-HIV-1 regi-
mens do not eliminate the virus in the organism, a
lifelong treatment is required. Problems associated
with adherence to HIV-1 treatment and to side ef-
fects of triple combination therapy shed the light on
the need of developing new e⁄cient strategies [15,27].
One major advantage of liposomes as drug carriers
is that their tissue distribution can be modulated
through variations of their lipid compositions. It is
thus possible to adapt the physicochemical properties
of liposomal formulations according to the desired
therapeutic objective. In the present study, the ability
of di¡erent types of liposomes to target HLA-DR
expressing cells and increase their accumulation in
secondary lymphoid organs has been evaluated.
The choice of the lipid compositions used in conven-
tional liposomes and immunoliposomes was based
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on our previous studies showing that these formula-
tions allowed e⁄cient targeting of lymphoid tissues
[25,32]. The use of 6% PEG in sterically stabilized
liposomes was selected as it was demonstrated that
a 5^10 mol% concentration of PEG results in a max-
imum circulation time [33]. Moreover, we have used
DSPE rather than DPPE because it was shown that
proteins linked to DSPE anchors leave the mem-
brane slower than DPPE [34]. In the case of sterically
stabilized immunoliposomes, a proper control would
have been to use liposomes containing 3.5% DSPE-
PEG and 2.5% DSPE-PEG-MAL. However, studies
Fig. 6. Fluorescent micrographs of spleen of C3H mouse at 48 h after the administration of a single subcutaneous dose of DiI steri-
cally stabilized liposomes (panel A), sterically stabilized immunoliposomes (panel C) and sterically stabilized liposomes bearing non-
speci¢c isotype-matching FabP fragments (panel E) to mice. Panels B, D and F represent the corresponding hematoxylin eosin colora-
tion of tissues. Figure shows the red pulp (RP) and the marginal zone (M) surrounding lymphoid nodule of the white pulp (WP).
Magni¢cation: 250U.
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performed in our laboratory showed that such for-
mulation led to unfavorable coupling reaction, most
likely because of the repulsive e¡ect of PEG chains
for proteins.
Our results demonstrated that the subcutaneous
injection of sterically stabilized liposomes bearing
anti-HLA-DR FabP fragments represents an attrac-
tive approach to speci¢cally target the lymphoid tis-
sues. The subcutaneous route of injection has been
selected since it constitutes the most appropriate
route for targeting lymph nodes [18,21,35]. In addi-
tion, it represents a simple route for patient self-ad-
ministration and it might serve as a depot for the
sustained release of drugs in vivo, reducing most
likely the frequency of liposomal drug administra-
tion. However, mechanisms upon which liposomes
reach lymph nodes are not well understood. It has
been postulated that the sequestration of liposomes
by these tissues could occur, either via a simple me-
chanical ¢ltration or by phagocytosis by cells of the
reticuloendothelial system [35]. In the case of me-
chanical ¢ltration, it is important to use liposomes
with a diameter less than 120 nm as it was shown
that the fenestration by which ¢ltration occurs is via
pores through such a diameter [21].
The e¡ect of PEG molecules on the surface of
liposomes has been extensively studied after intrave-
nous injection. It was shown that PEG prolonged the
circulation time of liposomes, reduced their uptake
by mononuclear phagocyte system and increased
their ability to cross in vivo biological barriers [36].
However, the e¡ect of steric stabilization of lipo-
somes following subcutaneous administration is not
well understood. It has been postulated that the pres-
ence of PEG could reduce the accumulation of lipo-
somes at the site of injection and therefore increase
their ability to move through the lymph [21,22]. Our
results have shown that the presence of PEG did not
substantially increase the accumulation of liposomes
in the regional lymph nodes as previously observed
[37]. However, it signi¢cantly increased the accumu-
lation of liposomes in lymph nodes far from the in-
jection site, suggesting that the presence of PEG may
reduce phagocytosis by cells of MPS increasing their
e⁄cacy to target other lymph nodes among the lym-
phatic vessels. As expected, the incorporation of
PEG did not reduce the accumulation of liposomes
in the spleen and liver.
Many coupling procedures of antibodies to steri-
cally stabilized liposomes have been proposed in the
literature [22,38^41]. In this study, anti-HLA-DR
FabP fragments were covalently attached to DSPE-
PEG-MPB via the interaction of sulfhydryl (FabP)
and maleimide (MPB) groups. Thioether linkage is
known to be one of the most useful and e⁄cient
reactions in bioconjugate chemistry. Moreover, we
have used PEG 2000 because it allows e⁄cient tissue
targeting and high circulation half-lives [22]. Higher
coupling e⁄ciencies of FabP fragments to liposomes
have been reported when FabP was attached at the
terminal end of PEG chains [41,42]. In our experi-
ments, the FabP^liposomes coupling e⁄ciency was in
the range of 15^20% for both conventional and steri-
cally stabilized liposomes, even if the concentration
of MPB in sterically stabilized liposomes was higher
than that of conventional liposomes (6% and 2.5%,
respectively). These results suggest that the amount
of MPB does not in£uence the coupling e⁄ciency of
FabP to the phospholipid vesicles. On the other hand,
our results along with those of others [43] showed
that the presence of free MPB on the surface of
conventional or sterically stabilized liposomes does
not in£uence attachment to cells in vitro or their
tissue distribution.
Our data showed that anti-HLA-DR immunolipo-
somes accumulated better in brachial and cervical
lymph nodes than that of conventional liposomes.
However, the presence of anti-HLA-DR FabP frag-
ments did not signi¢cantly enhance the liposomal
accumulation in other lymph nodes. Although the
coupling of FabP fragments rather than complete
IgG is known to eliminate a range of Fc-mediated
biological activities, like complement activation via
the classical pathway and humoral responses of
clearance via antibody^Fc receptor interactions, it
is possible that conventional immunoliposomes are
still rapidly taken up by cells of MPS present in
lymph, impairing their possibility to target other
lymphoid tissues far from the injection site. How-
ever, our results suggest that the attachment of
FabP fragments at the end termini of PEG reduces
the accumulation of liposomes at the injection site,
diminishes their rapid uptake by cells of MPS and
prolongs their circulation time improving their over-
all lymphatic uptake when compared to PEG-free
immunoliposomes. This hypothesis is supported by
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the fact that a higher concentration of sterically sta-
bilized immunoliposomes was observed in all lymph
nodes studied, especially at late time points, in lymph
nodes far from the injection site and in plasma. The
higher concentration of sterically stabilized immuno-
liposomes in plasma when compared to conventional
immunoliposomes could be attributed to the pres-
ence of PEG which reduces the binding of plasma
proteins prolonging thereby their circulation time.
Fluorescence microscopy studies demonstrated
that the localization of sterically stabilized anti-
HLA-DR immunoliposomes in lymphoid tissues
was completely di¡erent than that of sterically stabi-
lized liposomes. In fact, sterically stabilized lipo-
somes accumulated only in macrophage-rich areas
such as the subcapsular region of lymph nodes and
in the red pulp and marginal zone of the spleen.
Oussoren et al. have observed the presence of colloi-
dal gold particles in macrophages of regional lymph
nodes following the subcutaneous administration of
PEG-gold liposomes to mice [19]. It was hypothe-
sized that because of the slow progression of lipo-
somes through the lymph nodes, enough time was
available for e⁄cient interactions of the PEG lipo-
somal surface with phagocytic cell membranes. In
contrast, sterically stabilized immunoliposomes
highly accumulated in the deep cortex of lymph
nodes which contains aggregates of B-cells and FDCs
constituting the follicles. In HIV-1 infection, FDCs,
which reside in germinal centers, display HIV-1 par-
ticles on their surface to selectively activate B-cells.
CD4+ T-cells from the paracortical area migrate to
the germinal centers in response to B-cell activation
to be eventually infected. Our results showed that
sterically stabilized immunoliposomes highly accu-
mulate in these regions and could represent a con-
venient strategy to deliver drugs in this area of the
nodes inhibiting more e⁄ciently HIV-1 replication.
Moreover, the injection of sterically stabilized immu-
noliposomes resulted in an intense £uorescence signal
in the white pulp of the spleen, suggesting a selective
targeting of B-cells in the follicles and of macro-
phages present in the marginal zone surrounding
the lymphoid follicle.
The use of sterically stabilized immunoliposomes
could represent a convenient strategy to concentrate
anti-HIV-1 drugs at sites of infection, more particu-
larly within lymphoid organs. Such targeted delivery
system should reduce the dissemination of HIV-1
and preserve the FDC microenvironment that will
likely protect the infected host from developing the
characteristic immunode¢cient state. The improved
pharmacology of liposomal drugs could reduce the
dose and frequency of administration of antivirals
used in conventional therapy, facilitating drug com-
pliance and limiting the occurrence of drug resis-
tance. Given that HIV-1 particles acquire high
amount of host-derived HLA-DR proteins, the en-
capsulation of destabilizing agents into sterically sta-
bilized anti-HLA-DR immunoliposomes would be an
interesting approach to target free viral particles
trapped on FDC. The use of immunoliposomal drugs
in HIV-1 therapy could hopefully o¡er new alterna-
tives for the treatment of this retroviral infection.
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